Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic...
22 KB (2,133 words) - 06:05, 5 July 2024
Pertuzumab/trastuzumab/hyaluronidase, sold under the brand name Phesgo, is a fixed-dose combination medication to treat adults with HER2-positive breast...
12 KB (966 words) - 07:37, 1 July 2024
Mark Sliwkowski published the first studies with an antibody called 2C4 (pertuzumab or Perjeta), targeting the Her-2 molecule in breast and other cancers...
37 KB (3,213 words) - 19:58, 27 June 2024
(Herceptin Hylecta), daratumumab/hyaluronidase-fihj (Darzalex Faspro), and pertuzumab/trastuzumab/hyaluronidase–zzxf (Phesgo). In July 2021, the U.S. Food and...
31 KB (2,895 words) - 10:05, 2 June 2024
NCT01120184 for "A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab (Herceptin) Plus a Taxane in Patients...
29 KB (2,699 words) - 00:43, 10 February 2024
Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for hepatitis B and C. Perjeta (pertuzumab), for HER-2 positive breast cancer. Polatuzumab vedotin|Polivy (polatuzumab...
57 KB (5,236 words) - 09:00, 28 June 2024
pasudotox L01FC01 Daratumumab L01FC02 Isatuximab L01FD01 Trastuzumab L01FD02 Pertuzumab L01FD03 Trastuzumab emtansine L01FD04 Trastuzumab deruxtecan L01FD05 Trastuzumab...
12 KB (877 words) - 15:36, 25 January 2024
Randomization was stratified by hormone receptor status, prior treatment with pertuzumab, and history of visceral disease. The FDA approved trastuzumab deruxtecan...
25 KB (2,085 words) - 03:15, 6 July 2024
three weeks for twelve months. Adding a second HER2-targeted antibody, pertuzumab slightly enhances treatment efficacy. In rare cases, trastuzumab can disrupt...
129 KB (14,629 words) - 16:57, 29 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
68 KB (5,993 words) - 00:22, 20 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
92 KB (8,667 words) - 19:29, 28 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
121 KB (13,799 words) - 06:42, 1 July 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
31 KB (3,413 words) - 23:30, 21 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
150 KB (15,741 words) - 10:52, 27 June 2024
a protein that halts cell proliferation. Another monoclonal antibody, Pertuzumab, which inhibits dimerisation of HER2 and HER3 receptors, was approved...
43 KB (4,776 words) - 13:06, 5 July 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
42 KB (3,935 words) - 04:01, 30 April 2024
This is the first approved therapy for advanced BCC. 2012: Perjeta (pertuzumab): For use in combination with Herceptin (trastuzumab) and docetaxel chemotherapy...
38 KB (3,369 words) - 17:52, 24 May 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
10 KB (661 words) - 04:10, 26 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
12 KB (1,049 words) - 10:54, 12 January 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
11 KB (934 words) - 06:00, 10 April 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
17 KB (1,489 words) - 05:47, 7 April 2024
cancer therapy and the creation of the drugs trastuzumab (Herceptin) and pertuzumab (Perjeta). In 1995, after finishing his residency, Drebin became an assistant...
6 KB (567 words) - 20:49, 22 May 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
40 KB (4,580 words) - 05:24, 3 June 2024
Receptor tyrosine kinase ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab, Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab deruxtecan)...
12 KB (760 words) - 05:52, 10 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
27 KB (3,071 words) - 04:54, 3 June 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
23 KB (2,786 words) - 23:53, 26 April 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
22 KB (1,787 words) - 05:10, 1 July 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
5 KB (412 words) - 23:17, 19 June 2023
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
22 KB (1,993 words) - 23:37, 23 March 2024
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
71 KB (6,661 words) - 22:48, 2 July 2024